
-
MEI Pharma NasdaqCM:MEIP MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Location: 9920 Pacific Heights Blvd., Suite 250, San Diego, CA, 92121, United States | Website: https://meipharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-5.88M
Cash
20.47M
Avg Qtr Burn
-9.096M
Short % of Float
0.04%
Insider Ownership
1.31%
Institutional Own.
40.16%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ME-344 (Mitochondrial Inhibitor) + bevacizumab Details Cancer, Solid tumor/s, Colorectal cancer | Phase 1b Update | |
Zandelisib (Oral P13K Delta Inhibitor) Details B-cell malignancies | Failed Discontinued | |
Zandelisib (Oral P13K Delta Inhibitor) Details Follicular lymphoma | Failed Discontinued | |
Zandelisib (Oral P13K Delta Inhibitor) Details B-cell malignancies | Failed Discontinued | |
Voruciclib (CDK Inhibitor) +/- venetoclax Details B-cell malignancies, Acute myeloid leukemia, Cancer | Failed Discontinued |